News

Fierce Pharma1d
Novo moves past GLP-1 spat with Hims & Hers, tapping telehealth company to offer discounted Wegovy
Novo Nordisk appears to be letting compounded GLP-1 bygones be bygones—at least, in one respect. | Novo Nordisk appears to be ...
Why Novo Nordisk Stock Is Soaring Today
Shares of Novo Nordisk ( NVO 3.94%) are up on Tuesday. The company's stock gained 3.9% as of 2:40 p.m. ET today and was up as ...
Becker's Hospital Review1d
Federal court backs Novo Nordisk in crackdown on ‘knockoff’ GLP-1s: 5 notes
A federal court in Texas has bolstered Novo Nordisk’s efforts to limit the production and sale of compounded versions of its GLP-1 drugs, Wegovy and Ozempic. Here are five notes: ...
NJBIZ1d
Novo Nordisk scores court win against GLP-1 copycat compounders
A judge denied compounders' request to keep making off-brand Wegovy and Ozempic after the FDA removed semaglutide from its shortage list.
Hims & Hers Health: GLP-1 Deals De-Risk The Story
Hims & Hers Health partners with Novo Nordisk (NVO) to offer Wegovy, boosting weight-loss solutions. See why I remain ...
Novo Nordisk wins case to kick knockoff Ozempic off the market, but it may not last
Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.
Down 61%, Is Novo Nordisk Stock Worth Buying on the Dip?
Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...